A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia.
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs AUTO-3 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms AMELIA
- Sponsors Autolus
- 09 Feb 2018 Planned number of patients changed from 50 to 62.
- 19 Sep 2017 New trial record